Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



President Signs FDA User Fee Legislation


 
Sen. Lamar Alexander

On Aug. 18, President Donald Trump signed bipartisan legislation authored by Senate health committee Chairman Lamar Alexander (R-Tenn.) and Ranking Member Patty Murray (D-Wash.) intended to speed safe drugs and medical devices into patients' medicine cabinets and doctors' offices, while maintaining safety and effectiveness standards.

"The legislation signed by the president today will speed the FDA's work to review new cures and treatments and get them into patients' medicine cabinets and doctors' offices," Alexander said after the legislation was signed. "The first step was last year's passage of 21st Century Cures to spur medical research, and this is the next step -- legislation to help ensure that these breakthroughs in research make it to patients."

"I'm pleased that Democrats and Republicans in Congress were able to set aside partisanship, work together to put patients and families first, and ensure the FDA continues to have the resources it needs to advance safe, effective medical products for people across the country," Murray said. "This legislation reflects years of hard work by the Obama Administration, as well as members on both sides of the aisle, and I want to express my appreciation in particular to Chairman Alexander for his leadership. I hope we can build on this step forward with additional efforts to strengthen healthcare for the communities we all serve."

The legislation was passed by the Senate on Aug. 3 by a vote of 94-1.

The legislation includes four different user fee agreements that must be reauthorized by Sept. 30. The bill is virtually identical to legislation overwhelmingly approved by the Senate's health committee on May 11. This legislation will reauthorize the authority for the Food and Drug Administration (FDA) to accept user fees - paid by manufacturers of drugs and medical devices - that account for $8 to $9 billion over 5 years and is over a quarter of all FDA funding. The reauthorizations are based on recommendations from industry and FDA after a public process.

Over the last two years, the HELP Committee led by Alexander and Murray has held 15 bipartisan briefings, including some with the House Energy and Commerce Committee, to hear from FDA and industry about the reauthorization. The HELP Committee held two bipartisan hearings, on March 21 and April 4, on the medical device and drug user fees. The committee held a markup on the bill on May 11, when two bipartisan amendments were adopted, and the committee overwhelmingly approved the bill -- voting 21 to 2.

 
Share:

Related Articles:


Recent Articles

Increasing Number Of Tennesseans Dying From Drug Overdoses

Tennessee Department of Health data show 1,631 Tennesseans died from drug overdoses in 2016, the highest annual number of such deaths recorded in state history. This is an increase from the 1,451 overdose deaths recorded among Tennessee residents in 2015.

Read More

AMA Urges Congress to Take Swift Action to Retain DACA Program Protections

The American Medical Association sent a letter to Congress on Sept. 5 outlining why DACA is an American healthcare issue and urging legislators to take prompt action to ensure individuals with Deferred Action for Childhood Arrivals status are able to remain in the United States.

Read More

New Antiviral Drug Inhibits Epidemic SARS, MERS & More

A multi-institutional team of researchers has found a new antiviral drug candidate that could treat or prevent a number of potential pandemic outbreaks.

Read More

Disaster Preparedness: Are We Ready?

In a world of ever-evolving threats, the officials responsible for a community's health and safety must constantly update, evaluate, prepare and communicate their preparedness plan.

Read More

Addressing Opioid Addiction in America

Even as the AMA works with physicians and other providers to address opioid addiction, the national epidemic continues to evolve.

Read More

Moving Forward on Health Reform

THA's Craig Becker shares the hospital perspective on healthcare reform and what's needed to maintain access to care across Tennessee.

Read More

MGMA Releases 2017 Regulatory Burden Survey: MIPS Tops the List

The results of the Medical Group Management Association (MGMA) 2017 Regulatory Burden Survey reveal there is no shortage of opportunity to reduce regulatory burdens on physician practices.

Read More

In Case of Emergency

On Sept. 8, 2016 the final rule Emergency Preparedness Requirements for Medicare and Medicaid Participating Providers and Suppliers was published in the Federal Register. By Nov. 16, 2017, providers and suppliers must be in compliance.

Read More

Innovative Meharry Program Helps Mothers with Opioid Addiction

The Rainbow Program at Meharry offers pregnant and postpartum women with substance abuse disorders new hope.

Read More

The Osher Center: Healing Mind, Body & Spirit

Multi-faceted approach to pain management blends old and new therapies at The Osher Center for Integrative Medicine at Vanderbilt

Read More

Email Print
 
 

 

 


Tags:
FDA, Food & Drug Administration, HELP Committee, Lamar Alexander, Patty Murray, U.S. Senate
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: